HC Wainwright Cuts Aptose Biosciences (NASDAQ:APTO) Price Target to $2.00

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) had its price objective cut by HC Wainwright from $7.00 to $2.00 in a report published on Wednesday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Separately, StockNews.com started coverage on Aptose Biosciences in a report on Wednesday, November 13th. They set a “hold” rating on the stock.

Aptose Biosciences Trading Down 22.1 %

Shares of NASDAQ APTO opened at $0.19 on Wednesday. The stock has a market capitalization of $3.44 million, a PE ratio of -0.06 and a beta of 1.26. Aptose Biosciences has a twelve month low of $0.13 and a twelve month high of $2.91. The stock has a fifty day simple moving average of $0.38 and a 200-day simple moving average of $0.61.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC acquired a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences at the end of the most recent quarter. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.